A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family
This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing. Subsequently, we performed whole-genome sequencing to identify somatic mutations and analyze mutational signatures in individuals carrying the novel germline mutation. Our findings revealed a correlation between somatic mutational signatures and the BRCA1 germline mutation in the proband with ovarian cancer, while no such association was observed in the tumor tissue from the patient with breast cancer. F...
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Xiling Yang Li Shang Liren Yang Landi Sun Xiaoqian Tuo Sijia Ma Le Zhao Xu Li Wenfang Yang Source Type: research
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
CONCLUSIONS: Incorporation of standardized imaging characteristics to established clinical and lab predictors of outcome resulted in an improved predictive scoring system for patients with HCC.PMID:38159256 | DOI:10.1093/oncolo/oyad329 (Source: The Oncologist)
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Hop S Tran Cao Russell G Witt Khaled M Elsayes Ali A Baiomy Lianchun Xiao Sarah Palmquist Sunyoung S Lee Yehia I Mohamed Armeen Mahvash Ching-Wei D Tzeng Yun Shin Chun Eugene Jon Koay Asif Rashid Manal M Hassan James C Yao Jean-Nicolas Vauthey Ahmed O Kas Source Type: research
A Novel Germline Mutation of BRCA1 and Integrated Analysis With Somatic Mutation in a Chinese Multi-Cancer Family
This study investigated the genomic mutations in a Chinese family with a history of ovarian, breast, and rectal adenocarcinoma. A novel germline mutation (Phe1695Val) in BRCA1 was identified through whole-exome sequencing. Subsequently, we performed whole-genome sequencing to identify somatic mutations and analyze mutational signatures in individuals carrying the novel germline mutation. Our findings revealed a correlation between somatic mutational signatures and the BRCA1 germline mutation in the proband with ovarian cancer, while no such association was observed in the tumor tissue from the patient with breast cancer. F...
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Xiling Yang Li Shang Liren Yang Landi Sun Xiaoqian Tuo Sijia Ma Le Zhao Xu Li Wenfang Yang Source Type: research
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features
CONCLUSIONS: Incorporation of standardized imaging characteristics to established clinical and lab predictors of outcome resulted in an improved predictive scoring system for patients with HCC.PMID:38159256 | DOI:10.1093/oncolo/oyad329 (Source: The Oncologist)
Source: The Oncologist - December 30, 2023 Category: Cancer & Oncology Authors: Hop S Tran Cao Russell G Witt Khaled M Elsayes Ali A Baiomy Lianchun Xiao Sarah Palmquist Sunyoung S Lee Yehia I Mohamed Armeen Mahvash Ching-Wei D Tzeng Yun Shin Chun Eugene Jon Koay Asif Rashid Manal M Hassan James C Yao Jean-Nicolas Vauthey Ahmed O Kas Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Localized Myxofibrosarcoma: A Retrospective Analysis of Primary Therapy and Prognostic Factors in 134 Patients in a Single Institution
CONCLUSION: Adjuvant radiation had a positive impact on LRFS in all localized tumor stages, even in cT1 tumors. Chemotherapy did not have a significant impact on DMFS, regardless of tumor stage. Our findings indicate that myxofibrosarcoma may be a chemotherapy-resistant entity and a much closer monitoring is required, in case of neoadjuvant treatment.PMID:38141181 | DOI:10.1093/oncolo/oyad332 (Source: The Oncologist)
Source: The Oncologist - December 23, 2023 Category: Cancer & Oncology Authors: Athanasios Pogkas Peter Reichardt Per-Ulf Tunn Maya Niethard Mathias Werner Saeed Ghani Source Type: research
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
CONCLUSIONS: Our retrospective results suggest that HHIs should be continued after cCR to improve DFS in BCC.PMID:38127280 | DOI:10.1093/oncolo/oyad319 (Source: The Oncologist)
Source: The Oncologist - December 21, 2023 Category: Cancer & Oncology Authors: Salvatore Alfieri Rebecca Roman ò Sara Marceglia Vincenzo De Giorgi Ketty Peris Pietro Sollena Alfredo Piccerillo Ruggero Moro Giulio Gualdi Paolo Antonio Ascierto Marco Palla Miriam Paone Laura Eibenschutz Francesco Spagnolo Paola Queirolo Daria Maria F Source Type: research
Transarterial Radioembolization for Management of Hepatocellular Carcinoma
Oncologist. 2023 Dec 21:oyad327. doi: 10.1093/oncolo/oyad327. Online ahead of print.ABSTRACTTransarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment intent, including curative therapy, bridging to transplant, and downstaging disease, informs treatment approach and dosimetry goals. Radiation lobectomy (RL) and radiation segmentectomy (RS) are the 2 main forms of Y90 administration which have shown improved survival outcomes with the development of personalized dosimetry. RS aims to achieve complete...
Source: The Oncologist - December 21, 2023 Category: Cancer & Oncology Authors: Wali Badar Qian Yu Mikin Patel Osman Ahmed Source Type: research
Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
CONCLUSIONS: Our retrospective results suggest that HHIs should be continued after cCR to improve DFS in BCC.PMID:38127280 | DOI:10.1093/oncolo/oyad319 (Source: The Oncologist)
Source: The Oncologist - December 21, 2023 Category: Cancer & Oncology Authors: Salvatore Alfieri Rebecca Roman ò Sara Marceglia Vincenzo De Giorgi Ketty Peris Pietro Sollena Alfredo Piccerillo Ruggero Moro Giulio Gualdi Paolo Antonio Ascierto Marco Palla Miriam Paone Laura Eibenschutz Francesco Spagnolo Paola Queirolo Daria Maria F Source Type: research
